Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort
Objectives: Seroprevalence studies can provide a measure of SARS-CoV-2 cumulative incidence, but a better understanding of spike and nucleocapsid (anti-N) antibody dynamics following infection is needed to assess the longevity of detectability. Methods: Adults aged ≥18 years, from households enrolle...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-10-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971222004490 |
| _version_ | 1828747022981660672 |
|---|---|
| author | Annalan M D Navaratnam Madhumita Shrotri Vincent Nguyen Isobel Braithwaite Sarah Beale Thomas E Byrne Wing Lam Erica Fong Ellen Fragaszy Cyril Geismar Susan Hoskins Jana Kovar Parth Patel Alexei Yavlinsky Anna Aryee Alison Rodger Andrew C Hayward Robert W Aldridge Susan Michie Pia Hardelid Linda Wijlaars Eleni Nastouli Moira Spyer Ben Killingley Ingemar Cox Vasileios Lampos Rachel A McKendry Tao Cheng Yunzhe Liu Jo Gibbs Richard Gilson Anne M Johnson |
| author_facet | Annalan M D Navaratnam Madhumita Shrotri Vincent Nguyen Isobel Braithwaite Sarah Beale Thomas E Byrne Wing Lam Erica Fong Ellen Fragaszy Cyril Geismar Susan Hoskins Jana Kovar Parth Patel Alexei Yavlinsky Anna Aryee Alison Rodger Andrew C Hayward Robert W Aldridge Susan Michie Pia Hardelid Linda Wijlaars Eleni Nastouli Moira Spyer Ben Killingley Ingemar Cox Vasileios Lampos Rachel A McKendry Tao Cheng Yunzhe Liu Jo Gibbs Richard Gilson Anne M Johnson |
| author_sort | Annalan M D Navaratnam |
| collection | DOAJ |
| description | Objectives: Seroprevalence studies can provide a measure of SARS-CoV-2 cumulative incidence, but a better understanding of spike and nucleocapsid (anti-N) antibody dynamics following infection is needed to assess the longevity of detectability. Methods: Adults aged ≥18 years, from households enrolled in the Virus Watch prospective community cohort study in England and Wales, provided monthly capillary blood samples, which were tested for spike antibody and anti-N. Participants self-reported vaccination dates and past medical history. Previous polymerase chain reaction (PCR) swabs were obtained through Second Generation Surveillance System linkage data. The primary outcome variables were seropositivity and total anti-N and spike antibody levels after PCR-confirmed infection. Results: A total of 13,802 eligible individuals provided 58,770 capillary blood samples. A total of 537 of these had a previous positive PCR-confirmed SARS-CoV-2 infection within 0-269 days of antibody sample date, among them 432 (80.45%) having a positive anti-N result. Median anti-N levels peaked between days 90 and 119 after PCR results and then began to decline. There is evidence of anti-N waning from 120 days onwards, with earlier waning for females and younger age categories. Conclusion: Our findings suggest that anti-N has around 80% sensitivity for identifying previous COVID-19 infection, and the duration of detectability is affected by sex and age. |
| first_indexed | 2024-04-14T04:35:07Z |
| format | Article |
| id | doaj.art-8cb29b22a2e64be8b2e7cef278f83f53 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-04-14T04:35:07Z |
| publishDate | 2022-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-8cb29b22a2e64be8b2e7cef278f83f532022-12-22T02:11:54ZengElsevierInternational Journal of Infectious Diseases1201-97122022-10-01123104111Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohortAnnalan M D Navaratnam0Madhumita Shrotri1Vincent Nguyen2Isobel Braithwaite3Sarah Beale4Thomas E Byrne5Wing Lam Erica Fong6Ellen Fragaszy7Cyril Geismar8Susan Hoskins9Jana Kovar10Parth Patel11Alexei Yavlinsky12Anna Aryee13Alison Rodger14Andrew C Hayward15Robert W Aldridge16Susan Michie17Pia Hardelid18Linda Wijlaars19Eleni Nastouli20Moira Spyer21Ben Killingley22Ingemar Cox23Vasileios Lampos24Rachel A McKendry25Tao Cheng26Yunzhe Liu27Jo Gibbs28Richard Gilson29Anne M Johnson30Institute of Health Informatics, University College London, United KingdomInstitute of Health Informatics, University College London, United KingdomInstitute of Health Informatics, University College London, United KingdomInstitute of Health Informatics, University College London, United KingdomInstitute of Epidemiology and Health Care, University College London, London, United KingdomInstitute of Health Informatics, University College London, United KingdomInstitute of Health Informatics, University College London, United KingdomDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, United KingdomInstitute of Health Informatics, University College London, United KingdomInstitute of Health Informatics, University College London, United KingdomInstitute of Epidemiology and Health Care, University College London, London, United KingdomInstitute of Health Informatics, University College London, United KingdomInstitute of Health Informatics, University College London, United KingdomInstitute of Health Informatics, University College London, United KingdomInstitute for Global Health, University College London, London, United KingdomInstitute of Epidemiology and Health Care, University College London, London, United KingdomInstitute of Health Informatics, University College London, United Kingdom; Corresponding author: Prof Robert W Aldridge, Institute of Health Informatics, University College London, London, United Kingdom. Tel: 0207692000 ext 65541.Centre for Behaviour Change, University College London, London, UKDepartment of Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health, London, UKDepartment of Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health, London, UKDepartment of Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health, London, UK; Francis Crick Institute, London, UKDepartment of Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health, London, UK; Francis Crick Institute, London, UKDepartment of Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health, London, UK; Health Protection and Influenza Research Group, Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK; University College London Hospital, London, UKDepartment of Computer Science, University College London, London, UKDepartment of Computer Science, University College London, London, UKLondon Centre for Nanotechnology and Division of Medicine, London, University College London, UKSpaceTimeLab, Department of Civil, Environmental and Geomatic Engineering, University College London, London, UKSpaceTimeLab, Department of Civil, Environmental and Geomatic Engineering, University College London, London, UKInstitute for Global Health, University College London, London, UKInstitute for Global Health, University College London, London, UKInstitute for Global Health, University College London, London, UKObjectives: Seroprevalence studies can provide a measure of SARS-CoV-2 cumulative incidence, but a better understanding of spike and nucleocapsid (anti-N) antibody dynamics following infection is needed to assess the longevity of detectability. Methods: Adults aged ≥18 years, from households enrolled in the Virus Watch prospective community cohort study in England and Wales, provided monthly capillary blood samples, which were tested for spike antibody and anti-N. Participants self-reported vaccination dates and past medical history. Previous polymerase chain reaction (PCR) swabs were obtained through Second Generation Surveillance System linkage data. The primary outcome variables were seropositivity and total anti-N and spike antibody levels after PCR-confirmed infection. Results: A total of 13,802 eligible individuals provided 58,770 capillary blood samples. A total of 537 of these had a previous positive PCR-confirmed SARS-CoV-2 infection within 0-269 days of antibody sample date, among them 432 (80.45%) having a positive anti-N result. Median anti-N levels peaked between days 90 and 119 after PCR results and then began to decline. There is evidence of anti-N waning from 120 days onwards, with earlier waning for females and younger age categories. Conclusion: Our findings suggest that anti-N has around 80% sensitivity for identifying previous COVID-19 infection, and the duration of detectability is affected by sex and age.http://www.sciencedirect.com/science/article/pii/S1201971222004490Anti-NAnti-SSerosurveillanceCOVID-19Corona virus |
| spellingShingle | Annalan M D Navaratnam Madhumita Shrotri Vincent Nguyen Isobel Braithwaite Sarah Beale Thomas E Byrne Wing Lam Erica Fong Ellen Fragaszy Cyril Geismar Susan Hoskins Jana Kovar Parth Patel Alexei Yavlinsky Anna Aryee Alison Rodger Andrew C Hayward Robert W Aldridge Susan Michie Pia Hardelid Linda Wijlaars Eleni Nastouli Moira Spyer Ben Killingley Ingemar Cox Vasileios Lampos Rachel A McKendry Tao Cheng Yunzhe Liu Jo Gibbs Richard Gilson Anne M Johnson Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort International Journal of Infectious Diseases Anti-N Anti-S Serosurveillance COVID-19 Corona virus |
| title | Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort |
| title_full | Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort |
| title_fullStr | Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort |
| title_full_unstemmed | Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort |
| title_short | Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort |
| title_sort | nucleocapsid and spike antibody responses following virologically confirmed sars cov 2 infection an observational analysis in the virus watch community cohort |
| topic | Anti-N Anti-S Serosurveillance COVID-19 Corona virus |
| url | http://www.sciencedirect.com/science/article/pii/S1201971222004490 |
| work_keys_str_mv | AT annalanmdnavaratnam nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT madhumitashrotri nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT vincentnguyen nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT isobelbraithwaite nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT sarahbeale nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT thomasebyrne nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT winglamericafong nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT ellenfragaszy nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT cyrilgeismar nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT susanhoskins nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT janakovar nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT parthpatel nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT alexeiyavlinsky nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT annaaryee nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT alisonrodger nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT andrewchayward nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT robertwaldridge nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT susanmichie nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT piahardelid nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT lindawijlaars nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT eleninastouli nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT moiraspyer nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT benkillingley nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT ingemarcox nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT vasileioslampos nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT rachelamckendry nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT taocheng nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT yunzheliu nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT jogibbs nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT richardgilson nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort AT annemjohnson nucleocapsidandspikeantibodyresponsesfollowingvirologicallyconfirmedsarscov2infectionanobservationalanalysisintheviruswatchcommunitycohort |